3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older

BACKGROUND: PCV20 contains the 13-valent pneumococcal conjugate vaccine (PCV13) components, and 7 additional conjugates (for serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F), extending pneumococcal serotype coverage. Key data from the pivotal Phase 3 evaluation of PCV20 in adults are presented. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Essink, Brandon, Sabharwal, Charu, Xu, Xia, Sundaraiyer, Vani, Peng, Yahong, Moyer, Lisa, Pride, Michael W, Scully, Ingrid L, Jansen, Kathrin U, Gruber, William C, Scott, Daniel, Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776078/
http://dx.doi.org/10.1093/ofid/ofaa417.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776078/
http://dx.doi.org/10.1093/ofid/ofaa417.002

Ejemplares similares